title: Evidence of the selective alteration of anthracycline activity due to modulation by ICRF-187 (ADR-529).
abstract: Anthracyclines are powerful anticancer drugs whose use is limited by the development of chronic cardiotoxicity. The bisdioxopiperazine compound ICRF-187 (ADR-529) specifically abrogates this toxicity both in preclinical animal models and in humans. It does this without effecting either the acute toxicities or the anticancer activity. Therefore, with a specific antagonist, the mechanism of activity of the anthracyclines can be explored. This review discusses recent clinical trials and animal models addressing this issue and concludes by hypothesizing a mechanism of action.
authors: Department of Medical Oncology, The Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia.
authors: M D
authors: MD
authors: Green
authors: P
authors: P
authors: Alderton
authors: J
authors: J
authors: Gross
authors: F M
authors: FM
authors: Muggia
authors: J L
authors: JL
authors: Speyer
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D011929:Razoxane / Q000494:pharmacology*
chemical_list: D000903:Antibiotics, Antineoplastic; D011929:Razoxane